维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="DROLET DW"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma 显示文摘	Colagiovanni DB Drolet DW Langlois-Forget E	2012	Regul Toxicol Pharmacol2012，62，1：	1
2	Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer(NX1838) following injection into the vitreous humor of thesus monkeys显示文摘	Drolet DW Nelson J Tucker CE Zack PM Nixon K Bolin R	2000	Pham Res2000，17，12：	1
3	Pharmacokinetics and safety of an antivascular endothelial growth factor aptamer (NX1838)following injection into vitreous humor of rhesus monkeys显示文摘	Drolet DW Nelson J Tucker CE	2000	Pharm Res2000，17，：	1
4	A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications 显示文摘	Metry DW Haggstrom AN Drolet BA	2006	Am J Med Genet A2006，140，9：	1
5	A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX)显示文摘	Drolet DW Jenison RD Smith DE	1999	Comb Chem High Throughput Screen1999，2，5：	1
6	A prospective study of PHACE syndrome in infantile hemangiomas:demographic features,clinical findings,and complications显示文摘	Metry DW Haggstrom AN Drolet BA	2006	Am J Med Genet A2006，140，9：	1
7	Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys 显示文摘	DROLET DW NELSON J TUCKER CE	2000	Pharm Res2000，17，12：	1
8	A pros-pective study of PHACE syndrome in infantile heman-giomas:demographic features,clinical findings,and comp-lications显示文摘	Metry DW Haggstrom AN Drolet BA et a1	2006	Am J Med Genet A2006，140，9：	1
9	Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer(NX1838) following injectioninto the vitrous humor of rhesus monkeys显示文摘	Drolet DW Nelson J Tucker CE	2000	Pharm Res2000，17，12：	1
10	A nonclinical safety and pharmacokinetic evaluation of N6022:a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma显示文摘	Colagiovanni DB Drolet DW Langlois-Forget E	2012	Regul Toxicol Pharmacol2012，62，1：	1
11	A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX)显示文摘	Drolet DW Jenison RD Smith DE	1999	Comb Chem Hish Throughput Screen1999，2，5：	1
12	A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications 显示文摘	Metry DW Haggstrom AN Drolet BA	2006	Am J Med Genet A2006，140，9：	1
13	Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer ( NX1838 ) following injection into the vitreous humor of rhesus monkeys显示文摘	DROLET DW NELSON J TUCKER CE	2000	Pharm Res2000，17，12：	1
14	显示文摘	Drolet DW Nelson J Tucker CE	2000	Pharm Res2000，17，12：	1
15	A high throughput platform for systematic evolution of lig- ands by exponential enrichment (SELEX)显示文摘	Drolet DW Jenison RD Smith DE et a/	1999	Comb Chem High Throughput Screen1999，2，5：	1
16	A high throughput platform for systematic evolution of lig- ands by exponential enrichment (SELEX) 显示文摘	Drolet DW Jenison RD Smith DE	1999	Comb Chem High Throughput Screen1999，2，5：	1
17	A high throughput platform for systematic evolution of ligands by exponential enrichment显示文摘	Jenison RD Smith DE	1999	Com Che & Hig Thr Scr1999，2，5：	1
18	Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injectioninto the vitrous humor of rhesus monkeys显示文摘	Drolet DW Nelson J Tucker CE	2000	Pharm Res2000，17，12：	1
19	An enzymelinked oligonucleotide assay显示文摘	Drolet DW Moon-McDermott L Romig TS	1996	Nat Biotechnol1996，14，8：	1
20	A high through put platform for systematic evolution of ligands by expo nential enrichment显示文摘	Drolet DW Jenison RD Smith DE	1999	Corn Chem Hig Thr Scr1999，2271，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示